Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRA | P11474 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 4/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.37 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1727305 | 0.81 | HSD17B1 (0.43) | ESRRAESR1ESR2CAPN1 | |
| SCHEMBL1017182 | 0.78 | ESRRA (0.39) | ESRRAESR1ESR2CAPN1 | |
| SCHEMBL1014457 | 0.75 | ESRRA (0.45) | ESRRAESR1ESR2CAPN1 | |
| SCHEMBL2002689 | 0.73 | NR3C1 (0.38) | ESRRAESR1ESR2 | |
| SCHEMBL12532079 | 0.73 | ESR1 (0.36) | ESRRAESR1ESR2CAPN1 | |
| SCHEMBL1728583 | 0.73 | TRPA1 (0.37) | ESRRAESR1ESR2CAPN1 | |
| SCHEMBL1727693 | 0.73 | AR (0.40) | ESRRAESR1ESR2CAPN1 | |
| SCHEMBL1014014 | 0.71 | ESRRA (0.39) | ESRRAESR1ESR2CAPN1 | |
| SCHEMBL12151412 | 0.71 | ESRRA (0.34) | ESRRAESR1ESR2CAPN1 | |
| SCHEMBL1014345 | 0.70 | FFAR4 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012009617-A3 | METHODS, STORAGE MEDIUMS, AND SYSTEMS FOR ANALYZING PARTICLE QUANTITY AND DISTRIBUTION WITHIN AN IMAGING REGION OF AN ASSAY ANALYSIS SYSTEM AND FOR EVALUATING THE PERFORMANCE OF A FOCUSING ROUTING PERFORMED ON AN ASSAY ANALYSIS SYSTEM | LUMINEX CORPORATION (US) | 2012-05-10 | — | — | WO | claimed |
| EP-2271617-B1 | SUBSTITUTED 4-HYDROXY-N- (4-HYDROXYPHENYL) INDOLES AS ESTROGENIC AGENTS | GLAXO GROUP LTD (GB) | 2011-11-30 | — | — | EP | claimed |
| US-7956083-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2011-06-07 | — | — | US | claimed |
| US-20100324106-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | US | claimed |
| WO-2012009617-A3 | METHODS, STORAGE MEDIUMS, AND SYSTEMS FOR ANALYZING PARTICLE QUANTITY AND DISTRIBUTION WITHIN AN IMAGING REGION OF AN ASSAY ANALYSIS SYSTEM AND FOR EVALUATING THE PERFORMANCE OF A FOCUSING ROUTING PERFORMED ON AN ASSAY ANALYSIS SYSTEM | LUMINEX CORPORATION (US) | 2012-05-10 | — | — | WO | disclosed |
| EP-2271617-B1 | SUBSTITUTED 4-HYDROXY-N- (4-HYDROXYPHENYL) INDOLES AS ESTROGENIC AGENTS | GLAXO GROUP LTD (GB) | 2011-11-30 | — | — | EP | disclosed |
| US-7956083-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2011-06-07 | — | — | US | disclosed |
| US-7956083-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2011-06-07 | — | — | US | disclosed |
| US-7956083-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2011-06-07 | — | — | US | disclosed |
| EP-2271617-A1 | SUBSTITUTED 4-HYDROXY-N- (4-HYDROXYPHENYL) INDOLES AS ESTROGENIC AGENTS | Glaxo Group Limited (GB) | 2011-01-12 | — | — | EP | disclosed |
| US-20100324106-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | US | disclosed |
| US-20100324106-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | US | disclosed |
| US-20100324106-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | US | disclosed |
| WO-2009103710-A1 | SUBSTITUTED 4-HYDROXY-N- (4-HYDROXYPHENYL) INDOLES AS ESTROGENIC AGENTS | GLAXO GROUP LIMITED (GB) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324106-A1 | COMPOUNDS | ESR2, GPER1, ESR1 | ESRRA 6/4885ESR1 3/4885ESR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.